Nicolas Veziris

Nicolas Veziris

Auto-generated profile, based on publicly available information

Nicolas Veziris

Sorbonne Université, CNRS, Inserm, Centre d’Immunologie et des Maladies Infectieuses, CIMI, Paris, France

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2008 in Journal of Bacteriology
Verified
Journal Article
Closed access
MLMarie Lavollay
Marie Lavollay
MAMichel Arthur
Michel Arthur
MFMartine Fourgeaud
Martine Fourgeaud
LDLionel Dubost
Lionel Dubost
AMArul Marie
Arul Marie
JMJean-Luc Mainardi
Jean-Luc Mainardi
Our understanding of the mechanisms used by Mycobacterium tuberculosis to persist in a “dormant” state is essential to the development of therapies effective in sterilizing tissues. Gene expression profiling in model systems has revealed a complex adaptive response thought to endow M. tuberculosis with the capacity to survive several months of combinatorial antibiotic treatment. We show here that this adaptive response may involve remodeling of the peptidoglycan network by substitution of 4→3 cross-links generated by the d , d -transpeptidase activity of penicillin-binding proteins by 3→3 cross-links generated by a transpeptidase of l,d specificity. A candidate gene, previously shown to be upregulated upon nutrient starvation, was found to encode an l,d -transpeptidase active in the formation of 3→3 cross-links. The enzyme, Ldt Mt1 , was inactivated by carbapenems, a class of β-lactam antibiotics that are poorly hydrolyzed by the M. tuberculosis β-lactamases. Ldt Mt1 and carbapenems may therefore represent a target and a drug family relevant to the eradication of persistent M. tuberculosis .

1 February 2011 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
SBSylvaine Bastian
Sylvaine Bastian
NVNicolas Veziris
Nicolas Veziris
ARAnne-Laure Roux
Anne-Laure Roux
FBFlorence Brossier
Florence Brossier
JGJean-Louis Gaillard
Jean-Louis Gaillard
ECEmmanuelle Cambau
Emmanuelle Cambau
Clarithromycin was the drug of choice for Mycobacterium abscessus infections until inducible resistance due to erm (41) was described. Because M. abscessus was split into M. abscessus sensu stricto, Mycobacterium massiliense , and Mycobacterium bolletii , we looked for erm (41) in the three species and determined their clarithromycin susceptibility levels. Ninety strains were included: 87 clinical strains from cystic fibrosis patients (61%) and others (39%), representing 43 M. abscessus , 30 M. massiliense , and 14 M. bolletii strains identified on a molecular basis, and 3 reference strains. Clarithromycin and azithromycin MICs were determined by broth microdilution and Etest with a 14-day incubation period. Mutations in rrl (23S rRNA gene) known to confer acquired clarithromycin resistance were also sought. erm (41) was detected in all strains but with two deletions in all M. massiliense strains. These strains were indeed susceptible to clarithromycin (MIC 90 of 1 μg/ml) except for four strains with rrl mutations. M. abscessus strains harbored an intact erm (41) but had a T/C polymorphism at the 28th nucleotide: T28 strains (Trp10 codon) demonstrated inducible clarithromycin resistance (MIC 90 of >16 μg/ml), while C28 strains (Arg10) were susceptible (MIC 90 of 2 μg/ml) except for two strains with rrl mutations. M. bolletii strains had erm (41) sequences similar to the sequence of the T28 M. abscessus group, associated with inducible clarithromycin resistance (MIC 90 of >16 μg/ml). erm (41) sequences appeared species specific within the M. abscessus group and were fully concordant with clarithromycin susceptibility when erm (41) sequencing was associated with detection of rrl mutations. Clarithromycin-resistant strains, including the six rrl mutants, were more often isolated in cystic fibrosis patients, but this was not significantly associated with a previous treatment.

1 January 2006 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
AAAlexandra Aubry
Alexandra Aubry
NVNicolas Veziris
Nicolas Veziris
ECEmmanuelle Cambau
Emmanuelle Cambau
CTChantal Truffot-Pernot
Chantal Truffot-Pernot
VJVincent Jarlier
Vincent Jarlier
LFL. Mark Fisher
L. Mark Fisher
Mutations in the DNA gyrase GyrA 2 GyrB 2 complex are associated with resistance to quinolones in Mycobacterium tuberculosis . As fluoroquinolones are being used increasingly in the treatment of tuberculosis, we characterized several multidrug-resistant clinical isolates of M. tuberculosis carrying mutations in the genes encoding the GyrA or GyrB subunits associated with quinolone resistance or hypersusceptibility. In addition to the reported putative quinolone resistance mutations in GyrA, i.e., A90V, D94G, and D94H, we found that the GyrB N510D mutation was also associated with ofloxacin resistance. Surprisingly, several isolates bearing a novel combination of gyrA T80A and A90G changes were hypersusceptible to ofloxacin. M. tuberculosis GyrA and GyrB subunits (wild type [WT] and mutants) were overexpressed in Escherichia coli , purified to homogeneity, and used to reconstitute highly active gyrase complexes. Mutant proteins were produced similarly from engineered gyrA and gyrB alleles by mutagenesis. MICs, enzyme inhibition, and drug-induced DNA cleavage were determined for moxifloxacin, gatifloxacin, ofloxacin, levofloxacin, and enoxacin. Mutant gyrase complexes bearing GyrA A90V, D94G, and D94H and GyrB N510D were resistant to quinolone inhibition (MICs and 50% inhibitory concentrations [IC 50 s] at least 3.5-fold higher than the concentrations for the WT), and all, except the GyrB mutant, were less efficiently trapped as a quinolone cleavage complex. In marked contrast, gyrase complexes bearing GyrA T80A or A90G were hypersusceptible to the action of many quinolones, an effect that was reinforced for complexes bearing both mutations (MICs and IC 50 s up to 14-fold lower than the values for the WT). This is the first detailed enzymatic analysis of hypersusceptibility and resistance in M. tuberculosis .

15 October 2014 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
LGL. Guglielmetti
L. Guglielmetti
DDD. Le Du
D. Le Du
MJM. Jachym
M. Jachym
BHB. Henry
B. Henry
DMD. Martin
D. Martin
HSH. Saad
H. Saad
Bedaquiline is a new antibiotic that was approved for the treatment of multidrug-resistant (MDR) tuberculosis. We aimed to evaluate the short-term microbiological efficacy and the tolerability profile of bedaquiline. We performed a retrospective cohort study among patients with MDR tuberculosis receiving bedaquiline for compassionate use between January 2010 and July 2013 and evaluated at 6 months of bedaquiline treatment. A total of 35 patients with MDR tuberculosis were included in the study. Nineteen (54%) had extensively drug-resistant (XDR) tuberculosis, and 14 (40%) had isolates resistant to fluoroquinolones (Fqs) or second-line injectables. Bedaquiline was associated with a median of 4 (range, 2-5) other drugs, including linezolid in 33 (94%) cases. At 6 months of bedaquiline treatment, culture conversion was achieved in 28 of 29 (97%) cases with culture-positive pulmonary tuberculosis at bedaquiline initiation. Median time to culture conversion was 85 days (range, 8-235 days). Variables independently associated with culture conversion were treatment with a Fq (P = .01), absence of lung cavities (P < .001), and absence of hepatitis C virus infection (P = .001). A total of 7 patients (20%) experienced a ≥60-ms increase in QT interval, leading to bedaquiline discontinuation in 2 (6%) cases. Severe liver enzyme elevation occurred in 2 patients (6%). During the study period, 1 death (3%) occurred and was reported as unrelated to tuberculosis or antituberculosis treatment. The use of bedaquiline combined with other active drugs has the potential to achieve high culture conversion rates in complicated MDR and XDR tuberculosis cases, with a reassuring safety profile at 6 months of treatment.

1 May 2010 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
FBFlorence Brossier
Florence Brossier
NVNicolas Veziris
Nicolas Veziris
AAAlexandra Aubry
Alexandra Aubry
VJVincent Jarlier
Vincent Jarlier
WSWladimir Sougakoff
Wladimir Sougakoff
The GenoType MTBDR sl test rapidly detects resistance to ethambutol, fluoroquinolones, and second-line aminoglycosides (amikacin and kanamycin) and cyclic peptide (capreomycin) in Mycobacterium tuberculosis . A set of 41 multidrug-resistant (MDR) M. tuberculosis strains, 8 extensively drug-resistant (XDR) M. tuberculosis strains, and 3 non-MDR M. tuberculosis strains were tested by the MTBDR sl test and by DNA sequencing of the resistance-determining regions in gyrA and gyrB (fluoroquinolones [FQ]), rpsL (streptomycin), rrs and tlyA (aminoglycosides and/or cyclic peptide), and embB (ethambutol). The sensitivity and specificity of the MTBDR sl test were as follows: 87% and 96%, respectively, for fluoroquinolones; 100% for both for amikacin; 77% and 100%, respectively, for kanamycin, 80% and 98%, respectively, for capreomycin; and 57% and 92%, respectively, for ethambutol. Analysis of the discrepant results indicated that three FQ-resistant strains (including one XDR strain) with mutations in gyrB were missed by the MTBDR sl test and that one FQ-susceptible strain, identified as resistant by the MTBDR sl test, had a double mutation (T80A-A90G) in GyrA that did not confer resistance to FQ. Five strains (including two XDR strains) without mutations in rrs were monoresistant to aminoglycosides or cyclic peptide and were missed by the MTBDR sl test. Finally, 12/28 ethambutol-resistant strains had no mutation at codon 306 in embB , while 2/24 ethambutol-susceptible strains had such a mutation. In conclusion, the MTBDR sl test efficiently detects the most common mutations involved in resistance to fluoroquinolones, aminoglycosides/cyclic peptide, and ethambutol and accurately assesses susceptibility to amikacin. However, due to mutations not included in the test (particularly in gyrB ) or resistance mechanisms not yet characterized (particularly those related to ethambutol resistance and to monoresistance to aminoglycosides or cyclic peptide), the wild-type results yielded by the MTBDR sl test should be confirmed by drug susceptibility testing.

1 March 2007 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
MIM. Ibrahim
M. Ibrahim
KAK. Andries
K. Andries
NLN. Lounis
N. Lounis
ACA. Chauffour
A. Chauffour
CTC. Truffot-Pernot
C. Truffot-Pernot
NVN. Veziris
N. Veziris
In previous studies, the diarylquinoline R207910 (also known as TMC207) was demonstrated to have high bactericidal activity when combined with first- or second-line antituberculous drugs. Here we extend the evaluation of R207910 in the curative model of murine tuberculosis by assessing the activities of one-, two-, and three-drug combinations containing R207910 and isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), or moxifloxacin (MXF) in the setting of a high initial bacillary load (7.2 log 10 CFU). Two months of treatment with the combinations R207910-PZA, R207910-PZA-INH, R207910-PZA-RIF, or R207910-PZA-MXF resulted in culture-negative lung homogenates in 70 to 100% of the mice, while mice treated with INH-RIF-PZA (the reference regimen) or RIF-MXF-PZA remained culture positive. Combinations including R207910 but not PZA (e.g., R207910-INH-RIF and R207910-MXF-RIF) were less active than R207910-PZA-containing regimens administered either alone or with the addition of INH, RIF, or MXF. These results reveal a synergistic interaction between R207910 and PZA. Three-drug combinations containing these two drugs and INH, RIF, or MXF have the potential to significantly shorten the treatment duration in patients, provided that these results can be confirmed in long-term experiments including periods of relapse.